Most of available data showed that PPAR-γ antagonists (BADGE, GW9662) reversed the neuroprotective effects of PPAR-γ agonists, e.g., in SK-N-SH neuronal cells exposed to ischemia, in animal model of Parkinson’s disease (Kim et al. 2011; Garrido-Gil et al. 2012; Zeng et al. 2012). The gene discussed is PPARG; the disease is Parkinson disease.